Nearly two-thirds of patients who received Oruka Therapeutics’ (ORKA) experimental psoriasis treatment had completely clear skin after 16 weeks, the company said Monday. The midstage test results sent Oruka stock flying. Oruka is on track to take on blockbuster drugs from AbbVie and UCB. Last year, AbbVie’s (ABBV) Skyrizi brought in $17.6 billion in sales while Bimzelx, from UCB, notched…
